Scott Richard, MD
Gynecologic Oncology · Florham Park, NJNPI 1518002567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,300 of the $84,276 with a category attached, or 75.1%. 13 manufacturers reported payments, led by Clovis Oncology, Inc. at 59.9% of the total. Reporting peaked in 2019 at $64,119 and has fallen 99.3% since, to $430 in 2024. Among gynecologic oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $916.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$50K
- AstraZeneca$30K
- GSK$2K
- Dilon Technologies, Inc.$430
- Tesaro, Inc.$215
- Stryker$174
- plus $506 from 7 others
Across 4 payments — averaging $11,656 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$41K
- AstraZeneca$5K
What the payments were for
- Consulting fees$8,29310%
- Speaking & faculty fees$63,30075%
- Travel & lodging$9,00911%
- Food & beverage$3,6144%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 51 | $50,474 |
| AstraZeneca | 22 | $30,402 |
| GSK | 2 | $2,074 |
| Dilon Technologies, Inc. | 3 | $430 |
| Tesaro, Inc. | 4 | $215 |
| Stryker | 2 | $174 |
| Biom'up SA | 1 | $165 |
| Myriad Genetic Laboratories, Inc. | 1 | $96 |
| Coopersurgical, Inc. | 1 | $71 |
| Eisai Inc. | 1 | $67 |
| Baxter Healthcare | 2 | $65 |
| Merck | 1 | $28 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rubraca$49,824
- LYNPARZA$30,232
- ZEJULA$2,189
- HemoBlast Bellows$430
- HEMOBLAST$165
How this compares
$84,276 in reported general payments places this provider in the 95th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 14 | $27 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Florham Park
- Darlene GibbonFlorham Park$57
- Sharyn LewinTeaneck$968K
- Joyce VarughesePennington$16K
- James BosscherNeptune$13K
- Daniel TobiasMorristown$11K
- Karim ElsahwiNeptune$11K
- William BurkeParamus$9K
- Maria Schiavone ForlenzaTeaneck$8K
- Thad DenehyWest Orange$5K
- Shannon TomitaMorristown$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.